Hubei Biocause Pharmaceutical (000627) released a performance forecast on the evening of July 8th. The accumulated original insurance premium income of its controlling subsidiary, China Best Life Insurance Co., Ltd., from January 1st to June 30th, 2024 was approximately 24.608 billion yuan.
天茂集团：国华人寿上半年累计原保险保费收入约为246.08亿元
Hubei Biocause Pharmaceutical: China Best life insurance's accumulated original insurance premium income in the first half of the year was about 24.608 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.